Izvorni znanstveni članak
https://doi.org/10.3325/cmj.2013.54.480
Clinical significance of determining plasma homocysteine: case-control study on arterial and venous thrombotic patients
Biljana A. Vučković
; Department of Patophysiology Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia
Velibor S. Čabarkapa
; Department of Clinical Biochemistry, Centre for Laboratory Medicine, Clinical Centre of Vojvodina, Novi Sad, Serbia
Tatjana A. Ilić
; Department of Immunology, Clinic of Nephrology, Clinical Centre of Vojvodina, Novi Sad, Serbia
Iva R. Salatić
; Institute of Forensic Medicine, Clinical Centre of Vojvodina, Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia
Zagorka S. Lozanov-Crvenković
; Department of Mathematics and Informatics, Faculty of Sciences, University of Novi Sad, Novi Sad, Serbia
Gorana P. Mitić
; Department of Patophysiology Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia
Sažetak
Aim To determine the differences in plasma homocysteine
levels between three MTHFR 677 genotype subgroups in
patients with thrombosis and in controls, as well as between
patients with thrombosis and controls with the
same MTHFR 677 genotype.
Methods This case-control study was conducted in Clinical
Center of Vojvodina, Novi Sad, from June to December
2011. We included 65 patients with either arterial or
venous thrombosis (mean age, 40.97 ± 11.38 years) and 65
controls with no history or clinical evidence of any thrombotic
event (mean age, 41.23 ± 11.12 years). Patients and
controls were age- and sex-matched.
Results In comparison with controls, thrombotic patients
had significantly higher homocysteine levels (12.81 ± 4.94
μmol/L vs 9.82 ± 3.68 μmol/L; P < 0.001) and significantly
higher incidence of hyperhomocysteinemia (55% vs
22%; P < 0.001; odds ratio [OR] = 4.521). There were no significant
differences in homocysteine levels between homozygous
carriers, heterozygous carriers, and non-carriers
of the MTHFR 677 mutation in either thrombotic patients
(12.97 ± 5.40 μmol/L vs 12.55 ± 5.71 μmol/L vs 13.27 ± 1.71
μmol/L; P = 0.100) or controls (10.07 ± 2.50 μmol/L vs
10.25 ± 4.84 μmol/L vs 9.20 ± 2.44 μmol/L; P = 0.651). However,
in comparison with controls, homozygous carriers in
thrombotic patient group did not have significantly higher
levels of homocysteine (12.97 ± 5.40 μmol/L vs 10.07 ± 2.50
μmol/L; P = 0.072), but heterozygous carriers (12.55 ± 5.71
μmol/L vs 10.25 ± 4.84 μmol/L; P = 0.020) and non-carriers
(13.27 ± 1.71 μmol/L vs 9.20 ± 2.44 μmol/L; P < 0.001) did.
There was no significant difference in homocysteine levels
between patients with arterial and venous thrombosis
(12.76 ± 3.60 μmol/L vs 12.86 ± 5.51 μmol/L; P = 0.990) and
between patients with one thrombotic event and those
with recurrent thrombotic events (12.14 ± 3.20 μmol/L vs
15.25 ± 8.51 μmol/L; P = 0.254).
Conclusion Plasma homocysteine levels have a greater
clinical significance in the prevention of thrombosis and
managing its complications than MTHFR 677 genotyping.
Ključne riječi
Hrčak ID:
117013
URI
Datum izdavanja:
15.10.2013.
Posjeta: 1.049 *